Q32 Bio (QTTB) Restructuring Costs (2023)
Q32 Bio's quarterly Restructuring Costs came in at $2.7 million in Q4 2023, down 59.53% quarter-over-quarter from $6.6 million in Q3 2023.
Q32 Bio has reported Restructuring Costs for 1 years, with the latest figure at $2.7 million in Q4 2023.
- For the quarter ending Q4 2023, Restructuring Costs changed N/A year-over-year to $2.7 million; the trailing twelve-month figure through Dec 2023 stood at $9.3 million (changed N/A YoY), and the FY2023 full-year result was $9.3 million, changed N/A from the prior year.
- Restructuring Costs for Q4 2023 stood at $2.7 million, down from $6.6 million in the prior quarter.
- The five-year high for Restructuring Costs was $6.6 million in Q3 2023, with the low at $2.7 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 2.69 Mn |
| Sep 30, 2023 | 6.64 Mn |